Generation of a human iPSC line from a patient with a mitochondrial encephalopathy due to mutations in the GFM1 gene

Francisco Zurita-Díaz a,b,c, Teresa Galera-Monge a,b,c, Ana Moreno-Izquierdo c,d, Mario F. Fraga e, C. Ayuso b,f, Agustín F. Fernández g, Rafael Garese a,b,c, M. Esther Gallardo a,b,c,e

a Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols”, Facultad de Medicina (UAM-CSIC), Spain
b Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) Madrid, Spain
c Instituto de Investigación Hospital 12 de Octubre (‘i + 12’), Madrid, Spain
d Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols”, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
e Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Spain
f Servicio de Genética, Hospital 12 de Octubre, Madrid, Spain
g Instituto de Investigación Hospital 12 de Octubre (CIBERER) Madrid, Spain. Instituto de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) Madrid, Spain. Instituto de Investigación Sanitaria-University Hospital Fundacion Jimenez Diaz (IS-FJD, UAM), Madrid, Spain
h Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IOAPA), HUCA Universidad de Oviedo, Oviedo, Spain

1. Resource table:

<table>
<thead>
<tr>
<th>Name of stem cell line</th>
<th>GFM1SV.25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution</td>
<td>Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols”, Facultad de Medicina, (UAM-CSIC), and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) Madrid, Spain</td>
</tr>
<tr>
<td>Person who created resource</td>
<td>Francisco Zurita-Díaz</td>
</tr>
<tr>
<td>Contact person and email</td>
<td>M. Esther Gallardo, <a href="mailto:egallardo@iib.uam.es">egallardo@iib.uam.es</a></td>
</tr>
<tr>
<td>Date archived/stock date</td>
<td>August 18, 2015</td>
</tr>
<tr>
<td>Origin</td>
<td>Human skin cells</td>
</tr>
<tr>
<td>Type of resource</td>
<td>Biological reagent: induced pluripotent stem cells (iPSC) from a patient with a severe mitochondrial encephalopathy</td>
</tr>
<tr>
<td>Sub-type</td>
<td>Cell line</td>
</tr>
<tr>
<td>Key transcription factors</td>
<td>OCT3/4, SOX2, CMYC, KLF4</td>
</tr>
<tr>
<td>Authentication</td>
<td>Identity and purity of cell line confirmed (Fig. 1)</td>
</tr>
<tr>
<td>Link to related literature</td>
<td><a href="http://www.ncbi.nlm.nih.gov/pubmed/25852744">http://www.ncbi.nlm.nih.gov/pubmed/25852744</a></td>
</tr>
<tr>
<td>Information in public databases</td>
<td>None</td>
</tr>
</tbody>
</table>

2. Resource details

The generation of the human iPSC line, GFM1SV.25, was carried out using non-integrative Sendai viruses containing the reprogramming factors, OCT3/4, SOX2, CMYC, KLF4 (Takahashi et al., 2007). For this purpose, fibroblasts from a described patient with a severe mitochondrial encephalopathy were obtained (Brito et al., 2015). The patient’s fibroblasts carried two inherited heterozygous mutations in the GFM1 gene (c.1404delA; p.Gly469Valfs*84 and c.2011C>T; p.Arg671Cys). The presence of these mutations in the iPSC line was evaluated and confirmed by Sanger sequencing (Fig. 1A). GFM1SV.25 iPSC colonies displayed a typical ES-like colony morphology and growth behavior (Fig. 1B) and they stained positive for alkaline phosphatase activity (Fig. 1C). The endogenous expression of the pluripotency associated transcription factors OCT4, SOX2, KLF4, NANOG, CRIPTO and REX1 was also evaluated by RT-PCR (Fig. 1E). Immunofluorescence analysis revealed expression of transcription factors OCT4, NANOG, SOX2 and surface markers SSEA3, SSEA4, TRA1-60 and TRA1-81 characteristics of pluripotent ES cells (Fig. 1F). Promoters of the pluripotency associated genes, OCT4 and NANOG, heavily methylated in the original fibroblasts were almost demethylated in the GFM1SV.25 line suggesting an epigenetic reprogramming to pluripotency (Fig. 1G). The iPSC line has been adapted to feeder-free culture conditions and displays a normal karyotype (46,XX) after more than twenty culture passages (Fig. 1H). We also confirmed by DNA fingerprinting analysis that the line...
Fig. 1. Molecular and functional characterization of the GFM1SV.25 iPSC line. A. Electropherograms showing the mutations in the patient’s fibroblasts and in the GFM1SV.25 line. B. Typical ES-like colony morphology of the GFM1SV.25 iPSC line. C. Positive phosphatase alkaline staining. D. RT-PCR for detecting the clearance of the vectors and the exogenous reprogramming factor genes. E. qPCR showing the expression of the pluripotency associated markers OCT4, SOX2, KLF4, CRIPTO and REX1. F. Immunofluorescence analysis showing expression of typical pluripotent ES cell markers such as the transcription factors OCT4, NANOG, SOX2 and the surface markers SSEA3, SSEA4, TRA1-60 and TRA1-81; scale bars: 300 μm. G. Bisulfite pyrosequencing of the OCT4 and NANOG promoters. The promoters of the transcription factors OCT4 and NANOG were almost demethylated in the generated iPSC line. H. Karyotype analysis. GFM1SV.25 has a normal karyotype (46, XX). I. DNA fingerprinting analysis showing that GFM1SV.25 comes from the patient’s fibroblasts. J. Embryoid body based in vitro differentiation assays. GFM1SV.25 differentiates into all three germ layers, demonstrated by positive AFP endoderm staining (l), positive Tuj1 ectoderm staining and positive SMA mesoderm staining.
3. Materials and methods

3.1. Non-integrative reprogramming of mutant GFM1 fibroblasts into iPSC

All the experimental protocols included in the present study were approved by the Institutional Ethical Committee of the Autonoma University of Madrid according to Spanish and European Union legislation. Human fibroblasts from a described patient presenting with a severe mitochondrial encephalopathy associated with mutations in the GFM1 gene were used (Brito et al., 2015). For this purpose tissue fragments were obtained from a skin biopsy of this patient after informed consent. These fragments were directly plated in a dish with DMEM high glucose with 10% defined fetal bovine serum (Hyclone), 2 mM GlutaMAX and 1× Penicillin-Streptomycin (Life Technologies). After 3–4 weeks, fibroblasts outgrowing from the biopsy pieces will cover most of the dish and were expanded at 37 °C in 5% CO2 until the second passage. Subsequently, these fibroblasts were reprogrammed using the Cyto Tune–iPS 2.0 Sendai reprogramming kit following the instructions of the manufacturer. After eight passages of the iPSC line, silencing of the exogenous reprogramming factors genes and Sendai virus genome was confirmed by RT–PCR following the manufacturer’s instructions. GFM1SV.25 was maintained and expanded both on feeder layers and on feeder-free layers. In the first case, irradiated human fibroblasts feeders with ES medium containing: Knockout DMEM (Life Technologies), Knockout serum replacement 20%, (Life technologies), MEM non-essential amino acids solution 1× (Life technologies), GlutaMAX 1× (Life technologies), β-mercaptoethanol (100 μM), penicillin-streptomycin 1× (Life technologies) and bFGF (4 ng/ml) (Miltenyi Biotec) were used. Subsequently, GFM1SV.25 was adapted and cultured in feeder-free conditions on matrigel (354277, Corning) with mTeSR1 medium (StemCell) following the recommendations of the manufacturer.

For the propagation of the line, both enzymatic (dispase, collagenase IV and accumax) and mechanical procedures have been used.

3.2. Phosphatase alkaline analysis

The iPSC line GFM1SV.25 was seeded on a feeder layer plate. After seven days direct phosphatase alkaline activity was determined using the phosphatase alkaline blue membrane substrate solution kit (Sigma, AB0300) following the instructions of the manufacturer.

3.3. Mutation analysis

Total DNA from the patient’s fibroblasts and iPSCs was extracted using a standard phenol-chloroform protocol. Subsequently, amplification by PCR of the GFM1 gene region containing the c.1404delA mutation (exon 12) and the c.2011C>T mutation (exon 16) was carried out using the following primers: For detection of the c.1404delA mutation (GFM1-12F: 5′-TAT TGG GAT TAT AGG GGT GGG TTA-3′ and GFM1-12R: 5′-GGT AGA GGT TAA GGT GGG TTA-3′), Reverse-NANOG (5′- [B]tn - CCC AAC AAC AAA TAC TTC TAA ATT CAT CAC-3′), and sequencing primer OCT4_5′ (5′-ATA GGG GTG GGT TAT-3′); Forward-OCT4_3′ (5′-GGT GGT AGA GGT TAA GGT GGG TTA-3′), Reverse-OCT4_prox (5′-GGG GTT AGA GGT TAA GGT GTG TTT-3′); Forward-OCT4_dist (5′-TTT TGG TGG GGT ATT TGT GA-3′); Reverse-OCT4_dist (5′-[B]tn - AAA CTA CTC AAC CCC TCT CT-3′); and sequencing primer OCT4_5′_prox (5′-ATT TGT ATT GAG GGT TTT GA-3′). PCR was performed with primers biotinylated to convert the PCR product to single-stranded DNA templates, using the Vacuum Prep Tool. After PCR amplification, pyrosequencing reactions and methylation quantification were performed using PyroMark Q24 reagents, equipment and software (version 2.0.6, Qagen), according to the manufacturer’s instructions.

3.4. qPCR analyses

Total mRNA was isolated using TRIZOL and 1 μg was used to synthesize cDNA using the Reverse transcription CDNA synthesis kit. One μl of the reaction was used to quantify by qPCR the expression of the endogenous pluripotency associated genes (OCT4, SOX2, KLF4, NANOG, CRIPTO and REX1). Primers sequences were described by Aasen et al., 2008. All the expression values were normalized to the GAPDH housekeeping gene. Plots are representative of at least three independent experiments.

3.5. Bisulfite pyrosequencing

Bisulfite modification of genomic DNA was performed with the EZ DNA Methylation-Gold kit (Zymo Research) following the manufacturer’s instructions. The set of primers for PCR amplification and sequencing of NANOG and OCT4 were designed using the software PyroMark Assay Design (version 2.0.01.15; Qagen): Forward-NANOG (5′-TAT TGG GAT TAT AGG GGT GGG TTA-3′), Reverse-NANOG (5′-[B]tn - CCC AAC AAC AAA TAC TTC TAA ATT CAT CAC-3′), and sequencing primer OCT4_5′ (5′-ATA GGG GTG GGT TAT-3′); Forward-OCT4_3′ (5′-GGG GTT AGA GGT TAA GGT GGG TTA-3′), Reverse-OCT4_prox (5′-GGG GTT AGA GGT TAA GGT GGG TTA-3′); Forward-OCT4_dist (5′-TTT TGG TGG GGT ATT TGT GA-3′); Reverse-OCT4_dist (5′-[B]tn - AAA CTA CTC AAC CCC TCT CT-3′); and sequencing primer OCT4_5′_prox (5′-ATT TGT ATT GAG GGT TTT GA-3′). PCR was performed with primers biotinylated to convert the PCR product to single-stranded DNA templates, using the Vacuum Prep Tool. After PCR amplification, pyrosequencing reactions and methylation quantification were performed using PyroMark Q24 reagents, equipment and software (version 2.0.6, Qagen), according to the manufacturer’s instructions.

3.6. Karyotype analysis

Karyotype analyses of the iPSC line were carried out using cells with more than twenty culture passages. These cells were processed using standard cytogenetic techniques. Briefly, cells were treated with 10 μg/ml of Colcemid (Gibco) for 90 min at 37 °C, trypsinized, treated with 0.075 M hypotonic KCl solution, and fixed with Carnoy’s fixative. Cells were then dropped on a microscope glass slide and dried. Meta-phase cells were G banded using Wright staining. At least 20 metaphases were karyotyped.

3.7. Immunofluorescence analysis

Cells were grown on 0.1% gelatin-coated P35 culture plates (81156, Ibidi) and fixed with 4% paraformaldehyde. The following antibodies for the staining were used: TRA-1-60 (Millipore; MAB4360; 1:150); TRA-1-81 (Millipore; MAB4381; 1:150); SOX2, (Thermo Scientific; PA116968; 1:100); NANOG (R&D Systems; AF1997; 1:25); SSEA-4 (Millipore; MAB4304; 1:10); SSEA-3 (Millipore; MAB4303; 1:10); OCT4 (Santa Cruz Biotechnology; Sc-5279; 1:100); neuron-specific class III beta-tubulin (TuJ1) (Sigma, T8660; 1:300), α-fetoprotein (AFP) (Sigma, WH0000174M1, 1:300), smooth muscle alpha actin (SMA) (Sigma, A2547; 1:400). Secondary antibodies used were all from the Alexa Fluor Series from Jackson ImmunoResearch (all 1:500). Images were taken using a Zeiss confocal microscope.

3.8. In vitro differentiation assay

The in vitro pluripotency capacity of the iPSC line was tested by spontaneous embryoid body differentiation. For this purpose, iPSCs from a P100 plate with 80% of confluency were dissociated into a single cell suspension with accumax (SCR006, Millipore) and resuspended in 12 ml of mTeSR1 medium (Stemcell). Embryoid body formation was induced by seeding 120 μl of the iPSC suspension in each well of 96-well v-bottom low attachment plates and centrifuging the plates at 800 g for 10 min to aggregate the cells. After 2–3 days the embryoid bodies were transferred to an untreated P60 culture plate for 2–4 days. Subsequently, the embryoid bodies were transferred to 0.1% gelatin-coated
P35 culture plates (81156, Ibidi) and cultured in differentiation medium (DMEM F12 supplemented with 20% fetal bovine serum, 2 mM glutamine, 0.1 mM (β-mercaptoethanol, 1 x non essential amino acids and 1 x penicillin-streptomycin, all from Invitrogen) for 2–3 weeks to allow spontaneous endoderm formation. For mesoderm differentiation, iPSCs were maintained for 2–3 weeks in differentiation medium supplemented with 100 μM ascorbic acid (A4403, Sigma-Aldrich). For ectoderm differentiation, embryoid bodies were transferred to matrigel coated P35 culture plates and cultured in a special differentiation medium containing (50% DMEM F12, 50% neurobasal medium, 1 x GlutaMAX, 1 x penicillin-streptomycin, non essential aminoacids, 0.1 mM 2-mercaptoethanol, 1 x N2 supplement and 1 x B27 supplement, all from Invitrogen). In all the cases, the medium was changed every other day.

3.9. DNA fingerprinting analysis

For DNA fingerprinting analysis, highly polymorphic regions containing short tandem repeated sequences of DNA have been evaluated. For this purpose, the following markers (D13S317, D7S820, VWA, D8S1179, D21S11, D19S433, D2S1338 and amelogenin for sex determination) have been amplified by PCR and analyzed by ABI PRISM 3100 Genetic analyzer and Peak Scanner v3.5 (Applied Biosystems). Primer sequences and PCR conditions are available upon request.

Author disclosure statement

There are no competing financial interests in this study.

Acknowledgments

This work was supported by grants from the “Centro de Investigación Biomédica en Red en enfermedades raras” (CIBERER) (Grant 13-717/132.05 to RG), the “Instituto de Salud Carlos III” [Fondo de Investigación Sanitaria and Regional development fund (ERDF/ FEDER) funds PI10/0703 and PI13/00556 to RG and PI15/00484 to MEG], “Comunidad Autónoma de Madrid” (Grant number S2010/BMD-2402 to RG); TG receives grant support from the Universidad Autónoma de Madrid (FPI-UAM) and FZD from the Ministerio de Educación, Cultura y Deporte (Grant FPU13/00544). MEG is staff scientist at the “Centro de Investigación Biomédica en Red en Enfermedades Raras” (CIBERER).

References

